The most common biomarkers are tumor-specific antigens such as HER2/neu for breast cancer, genetic mutations such as EGFR mutation of lung cancer, or cancer-associated proteins like PSA for prostate cancer. This evidence concerns the gene ERBB2 and breast carcinoma.